The N-terminal fraction of desmoglein 3 encompassing its immunodominant domain is present in human serum: Implications for pemphigus vulgaris autoimmunity

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 2, 2006, Pages 399-407

  Lanza, Alessandro ^a   Femiano, F ^a   De Rosa, A ^a   Cammarota, M ^a   Lanza, M ^a   Cirillo, N ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Autoimmunity; Desmoglein 3; Pemphigus vulgaris; sDsg3; Tolerance

Indexed keywords

DESMOGLEIN 3; GLYCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FRACTIONATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOPRECIPITATION; IMMUNOREGULATION; KERATINOCYTE; MUCOSA; PEMPHIGUS VULGARIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN; T LYMPHOCYTE; WESTERN BLOTTING;

EID: 33746794618     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200601900216     Document Type: Article

References (34)

1. Stanley J.R. 1990. Pemphigus: skin failure mediated by autoantibodies. JAMA 264:1714.
2. Bystryn J.C. and J.L. Rudolph. 2005. Pemphigus. Lancet 366:61.
3. Wolff K. and E. Schreiner. 1971. Ultrastructural localization of pemphigus autoantibodies within the epidermis. Nature 229:59.
4. Shimizu A., A. Ishiko, T. Ota, K. Tsunoda, S. Koyasu, M. Amagai and T. Nishikawa. 2002. Ultrastructural changes in mice actively producing antibodies to desmoglein 3 parallel those in patients with pemphigus vulgaris. Arch. Dermatol. Res. 294:318.
5. Harman K.E., P.T. Seed, M.J. Gratian, B.S. Bhogal, S.J. Challacombe and M.M. Black. 2001. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br. J. Dermatol. 144:775.
6. Amagai M., V. Klaus-Kovtun and J.R. Stanley. 1991. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869.
7. Huber O. 2003. Structure and function of desmosomal proteins and their role in development and disease. Cell. Mol. Life Sci. 60:1872.
8. Runswick S.K., M.J. O'Hare, J.L. Jones, C.H. Streuli and D.R. Garrod. 2001. Desmosomal adhesion regulates epithelial morphogenesis and cell positioning. Nat. Cell. Biol. 3:823.
9. Syed S.H.E., B. Trinnaman, S. Martin, S. Major, J. Huchinson and A.I. Magee. 2002. Molecular interaction between desmosomal cadherins. Biochem. J. 362:317.
10. Mahoney M.G., Z.H. Wang, K. Rothenberger, P.J. Koch, M. Amagai and J.R. Stanley. 1999. Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J. Clin. Invest. 103:461.
11. Amagai M., S. Karpati, R. Prussick, V. Klaus-Kovtun and J.R. Stanley. 1992. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J. Clin. Invest. 90:919.
12. Futei Y., M. Amagai, M. Sekiguchi, K. Nishifuji, Y. Fujii and T. Nishikawa. 2000. Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris. J. Invest. Dermatol. 115:829.
13. Sekiguchi M., Y. Futei, Y. Fujii, T. Iwasaki, T. Nishikawa and M. Amagai. 2001. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J. Immunol. 167:5439.
14. Tsunoda K., T. Ota, M. Aoki, T. Yamada, T. Nagai, T. Nakagawa, S. Koyasu, T. Nishikawa and M. Amagai. 2003. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J. Immunol. 170:2170.
15. Bhol K., K. Natarajan, N. Nagarwalla, A. Mohimen, V. Aoki and R.A. Ahmed. 1995. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 92:5239.
16. Lin M.S., S.J. Swartz, A. Lopez, X. Ding, M.A. Fernandez-Vina, P. Stastny, J.A. Fairley and L.A. Diaz. 1997. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest. 99:31.
17. Nishifuji K., M. Amagai, M. Kuwana, T. Iwasaki and T. Nishikawa. 2000. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J. Invest. Dermatol. 114:88.
18. Veldman C., A. Stauber, R. Wassmuth, W. Uter, G. Schuler and M. Hertl. 2003. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J. Immunol. 170:635.
19. Veldman C., A. Hohne, D. Dieckmann, G. Schuler and M. Hertl. 2004. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol. 172:6468.
20. Wucherpfennig K.W. and J.L. Strominger. 1995. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. 7. Exp. Med. 181:1597.
21. Hertl M., M. Amagai, H. Sundaram, J. Stanley, K. Ishii and S.I. Katz. 1998. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J. Invest. Dermatol. 110:62.
22. Veldman C., K.L. Gebhard., W. Uter, R. Wassmuth, J. Grotzinger, E. Schultz and M. Hertl. 2004. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J. Immunol. 172:3883.
23. Amagai M., P.J. Koch, T. Nishikawa and J.R. Stanley. 1996. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J. Invest. Dermatol. 106:351.
24. Amagai M., K. Tsunoda, D. Zillikens, T. Nagai and T. Nishikawa. 1999. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J. Am. Acad. Dermatol. 40:167.
25. Pasdar M. and W.J. Nelson. 1989. Regulation of desmosome assembly in epithelial cells: kinetics of synthesis, transport and stabilization of desmoglein I, a major protein of the membrane core domain. J. Cell. Biol. 109:163.
26. Memar O., B. Christensen, S. Rajaraman, R. Goldblum, S.K. Tyring, M.M. Brysk, D.J. McCormick, H. El Zaim, J.L. Lan and B.S. Prabhakar. 1996. Induction of blister-causing antibodies by a recombinant full-length, but not the extracellular, domain of the pemphigus vulgaris antigen (desmoglein 3). J. Immunol. 157:3171.
27. Lucchese A., A. Mittelman, M.S. Lin, D. Kandur and A.A. Sinha. 2004. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 Mab 5H10. J. Transl. Med. 2:43.
28. Drachman D.B. 1994. Myasthenia gravis. N. Engl. J. Med 330:1797.
29. Abbas K.A., J. Lohr, B. Knoechel and V. Nagabhushanam. 2004. T cell tolerance and autoimmunity. Autoimmun. Rev. 3:471.
30. Singh N.J. and R.H. Schwartz. 2003. The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells. J. Exp. Med 198:1107.
31. Tanchot C., D.L. Barber, L. Chiodetti and R.H. Schwartz. 2001. Adaptive tolerance of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation. J. Immunol. 167:2030.
32. Goodnow C.C., R. Brink and E. Adams. 1991. Breakdown of self-tolerance in anergic B lymphocytes. Nature 352:532.
33. Fulcher D.A., A.B. Lyons, S.L. Korn, M.C. Cook, C. Koleda, C. Parish, B. Fazekas de St Groth and A. Basten. 1996. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J. Exp. Med. 183:2313.
34. Palmer J.P., C.M. Asplin, P. Clemons, K. Lyen, O. Tatpati, P.K. Raghu and T.L. Raquette. 1983. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222:1337.